FDA clears teclistamab plus daratumumab after first relapse, delivering striking PFS gains—plus practical tips to manage CRS, ICANS, and infections.
Shahrier Hossain, PharmD, BCOP
Advertisement
Articles by Shahrier Hossain, PharmD, BCOP
Belantamab mafodotin reenters clinical practice after FDA reapproval, signaling new potential for difficult-to-treat myeloma.
Advertisement
Latest Updated Articles
Tec-Dara: Match Made in Heaven or Double Trouble?June 16th 2026
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
2
Workforce Preparation for Fall Immunization Season Starts Now
3
Clinical Forum Events Highlight the Evolving Landscape of Obesity Management
4
Antibody-Drug Conjugates and HER2 Guidelines Are Reshaping Breast Cancer Treatment
5